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Background: A retrospective study to compare the failure patterns and effects of elective nodal irradiation (ENI) or
involved field irradiation (IFI) for cervical and upper thoracic esophageal squamous cell carcinoma (SCC) patients.
Methods: One hundred and sixty nine patients with the cervical and upper thoracic esophageal SCC were analyzed
retrospectively; 99 patients (59%) underwent IFI and 70 patients (41%) received ENI. We defined “Out-PTVifi in-PTVeni
metastasis” as lymph node metastasis occurring in the cervical prophylactic field of PTVeni thus out of PTVifi.
Results: Out-PTVifi in-PTVeni cervical node metastasis occurred in 8% of patients in the IFI group, all within 2 years
after treatment. However, it occurred in 10% of patients in the ENI group, and these failures happened gradually since
one year after treatments. No difference was found in OS and the incidences of Grade≥ 3 treatment-related esophageal
and lung toxicities between the two groups.
Conclusions: ENI for cervical and upper thoracic esophageal SCC patients did not bring longer OS and better long-term
control of cervical lymph nodes. Although ENI might delay cervical nodes progression in elective field; it could
not decrease the incidence of these failures.
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Esophageal carcinoma is one of the most common cancers
in the world with an estimated 482,300 new cases and
406,800 deaths yearly worldwide [1]. Definitive chemora-
diotherapy is widely used as the standard of care [2-4].
Whether ENI should be performed has always been a
controversy, especially for cervical and upper thoracic
esophageal squamous cell carcinoma (SCC). We retrospect-
ively studied different failure patterns for patients
who had ENI and who had not, investigated the
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Patient selection criteria
Patients who met the following criteria were included
for this study: (1) confirmation of esophageal SCC by
histology or cytology; (2) no prior therapy (what therapy?);
(3) no previous malignancies; (4) complete clinical data;
(5) tumors proved to be located in cervical or upper
thoracic esophagus by endoscopy. Patients who had been
treated with surgery were excluded. A total of 350 con-
secutive patients with esophageal cancer were treated
with definitive chemoradiotherapy at a single institution
(Fudan University Shanghai Cancer Center) between
January 1, 2008 and December 31, 2010. Among them, 169
patients had the tumors located in the cervical or upper
thoracic esophagus. Patients were staged according to the
American Joint Commission (AJCC) 6th edition criteria.
Initial staging consisted of a history and medical examin-
ation, routine blood tests, endoscopy, esophageal barium
radiography and a chest computed tomography (CT).
Sixty- two patients had PET-CT before treatments.This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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declined PET-CT for no reason. Informed consent was ob-
tained from each patient. This study was conducted in line
with the guidelines of the World Medical Association and
Declaration of Helsinki. The ethics committee of the Insti-
tutional Review Board of Shanghai Cancer Center approved
the study. Details of failure patterns were documented from
pre- and post-treatment CT, PET/CT scans, or endoscopy.
Patient characteristic
From January 1, 2008 to December 31, 2010, a total of 169
patients with cervical and upper esophageal SCC were
selected from 350 consecutive patients. The baseline charac-
teristics of the 169 patients were shown in Table 1. One-
hundred and twenty-eight patients were male and 41were
female. The median age was 60 years old (range: 37–90
years). Eighteen patients had cervical esophageal SCC, and
151 had upper thoracic esophageal SCC. Eighty-two patients
presented with Stage I-II disease, and 87 were Stage III-IV.
The tumor lengths in long axis measured in barium esopha-
gogram were <5 cm in 70 cases, 5–10 cm in 83 and >10 cm
in 16. Seventy patients (41%) received ENI, and 99 patients
(59%) did not. The baseline patient characteristics were bal-
anced between the ENI group and the IFI group (Table 1).
Radiotherapy
All patients underwent CT simulation in the supine pos-
ition, with CT images obtained at a 5-mm or 8-mm
thickness throughout the entire neck and thorax. TheTable 1 Patients’ characteristics
Characteristics IFI (%) ENI (%) P value
Sex
Male 74 (75%) 54 (77%) 0.679
Female 25 (25%) 16 (23%)
TNM stage
I-II 49 (49%) 33 (47%) 0.509
III-IV 50 (51%) 37 (53)
Median age (year) 62 58 0.574
Tumor length
<5 cm 43 (43%) 27 (39%) 0.416
5-10 cm 47 (47%) 36 (51%)
>10 cm 9 (10%) 7 (10%)
Tumor location
cervical esophagus 9 (10%) 9 (13%) 0.480
upper thoracic 90 (90%) 61 (87%)
Nodal status
N0 42 (42%) 22 (32%)
Local nodes 40 (40%) 31 (44%)
Distal nodes 17 (18%) 17 (24%) 0.288GTV and the PTV were defined as followed. According
to different PTV delineations, all the patients were divided
into two groups: the ENI group and the IFI group.
Irradiation plan of IFI: The gross tumor volume (GTV)
was defined as any primary tumors shown on the CT, or
barium esophagogram, and mediastinal lymph nodes with
the short axis of >10 mm and the cervical lymph nodes
with the short axis of > =10 mm. For the planning target
volume (PTV), a 1 cm margin was added around GTV, but
3 cm margins in the esophageal long axis superiorly and
inferiorly to encompass potential submucosal invasions.
Irradiation plan of ENI: The definition for GTV was the
same as that of IFI. The planning target volume (PTV)
enclosed GTV and clinical target volume (CTV) which cov-
ered supraclavicular area with the upper margin at the caudal
edge of cricoid cartilage, inferior margin at the sternal notch.
The CT data were registered in the treatment planning
system (Pinnacle). Radiotherapy was delivered using 6
MV photons with multi-leaf collimator (MLC). To verify
the field coverage, before treatment, the field size and
position were confirmed by re-simulation. Portal images
were done by an electron portal image device (EPID) to
ensure the correctness of field and patient position.
Plan optimization was based on the dose-volume histo-
gram (DVH), as follows: (1) the prescribed isodose curve
covered 95% of the PTV; (2)the 95% isodose curve covered
99% of the PTV.(3) the maximum dose within the PTV
was not allowed to exceed 110% of the prescribed dose.
The dose constraints to the organs at risk were as follows:
(1) the mean lung dose (MLD) was ≤15 Gy, and the V20
was ≤30%; (2) the mean heart dose (MHD) was ≤30 Gy;
and (3) the maximum spinal cord dose was ≤45 Gy.
Doses to primary lesion and metastatic nodes were
60–68.4Gy, and 50.4-54Gy for elective node irradiation.
The choice of ENI or IFI was physician dependent.
Chemotherapy regimen
One hundred and forty-nine patients had PF regimen
(cisplatin and 5-fluorouracil), 17 TP (taxane and cisplatin),
and 3 TPF (taxane, cisplatin and 5-fluorouracil).
Definition of failure patterns
“PTVifi” means the PTV in IFI mode (Blue line in
Figure 1).
“PTVeni” means the PTV in ENI mode (Green line in
Figure 1).
“In-PTVifi recurrence” was referred to esophageal
and/or regional lymph node failures within PTVifi.
“Out-PTVifi in-PTVeni metastasis” was referred to as
lymph nodes metastasis occurred in the cervical prophy-
lactic field of PTVeni thus out of PTVifi (Orange area in
Figure 1).
“Out-PTVeni metastasis” was referred to lymph nodes
metastasis occurred out of PTVeni.
Figure 1 Failure patterns of the IFI group and the ENI group. ENI = elective nodal irradiation. Red: GTV; Blue: IFI field in the coronal direction;
Green: ENI field in the coronal direction; Orange: the Out-PTVifi in-PTVeni field.
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evidences of radiology including PET/CT. The confirm-
ation of cervical nodes metastasis during the follow-up
time relied on the biopsy and histology. We also consi-
dered different failures within 6 months as simultaneous
failures.
Toxicity
Treatment-related acute toxicity was scored by the RTOG
criteria, including both acute and late injuries in either
esophagus or lung. The observation started from the first
day of treatment until death or the last follow-up visit.
Statistics
Overall survival rate (OS), locoregional recurrence rate,
distant metastasis rate and the incidence of lymph nodes
metastasis were the primary endpoints. The Chi-square
tests were used to compare the baseline characteristics
between the two groups. The Kaplan-Meier methods were
used to estimate these endpoints. Log-rank tests were used
to compare the overall survival curves. The parameters
were analyzed with respect to OS using the univariate and
the multivariate analysis of Cox regression, including age,
gender, TNM stage, nodal status, tumor length, ENI or IFI.
All analysis was performed using SPSS 16.0 (SPSS Inc,
Chicago, IL). The level of significance was set as p <0.05.
Results
Survival
Patients were followed until death or from 14 months to
59 months (median, 30 months) in those alive at lastevaluation on December 31th, 2012. At the last follow-
up visit, 76 patients (45%) were still alive. The 3-year OS
rate for the entire group was 48%, and the median OS
time was 27 months (95% Confidence Interval: 21–33
months). Three-year OS for the IFI group and the ENI
group were 49% and 47%, respectively (p = 0.741). In
multivariate analysis, TNM stage (p < 0.001), nodal status
(p = 0.020) and tumor length (p = 0.036) independently
predicted OS.
Failure patterns
Failure patterns for the entire group were demonstrated
in Table 2 and Figure 1. No significant difference was
found between the IFI group and the ENI group regarding
in field recurrences (p = 0.866) and distal organ metastasis
(p = 0.728).
Isolated out-PTVifi in-PTVeni cervical nodes metasta-
sis occurred in 3 patients (3%) in the IFI group and 2 pa-
tients (3%) in the ENI group. Out-PTVifi in-PTVeni
cervical nodes metastasis simultaneously with other fail-
ures happened in 5 patients (5%) in the IFI group and
also 5 patients (7%) in the ENI group, respectively.
Collectively, there were a total of 8 patients (8%) in the
IFI group with out-PTVifi in-PTVeni cervical nodes pro-
gress, and 7 patients (10%) in the ENI group with these
failures.
The detailed conditions, further progressions and sal-
vage treatments for the 15 patients were demonstrated in
Table 3, and the probabilities of out-PTVifi in-PTVeni
cervical nodes metastasis were showed in Figure 2. No
significant difference was found between the IFI group
Table 2 Failure patterns of IFI group and ENI group
IFI (n = 99, 100%) ENI (n = 70, 100%)
Failure 53 (53%) 41 (59%)
In field recurrence 32 (32%) 21 (30%)
Alone 27 (27%) 17 (24%)
+ out-PTVeni cervical nodes 1 (1%) 1 (1%)
+ out-PTVifi in-PTVeni nodes 4 (4%) 3 (4%)
Isolated out-PTVifi in-PTVeni nodes 3 (3%) 2 (3%)
Isolated out-PTVeni cervical nodes 0 0
Out-PTVeni mediastinal nodes 2 (2%) 2 (3%)
Alone 0 0
+ out-PTVifi in PTVeni nodes 0 1 (1%)
+ with other distal nodes 2 (2%) 1 (1%)
Distal organ metastasis 15 (15%) 14 (20%)
Alone 8 (8%) 7 (10%)
+ in field recurrence 6 (6%) 5 (7%)
+ out-PTVifi in-PTVeni nodes 1 (1%) 2 (3%)
Secondary esophageal tumor 1 (1%) 2 (3%)
Alone 1 (1%) 1 (1%)
+ out-PTVifi in-PTVeni nodes 0 1 (1%)
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cervical nodes metastasis (p = 0.741). However, we found
that for the patients in the IFI group, all the out-PTVifi
in-PTVeni metastatic cervical nodes occurred within
2 years after treatments. However, for the patients in the
ENI group, out-PTVifi in-PTVeni cervical nodes metas-
tasis happened gradually since one year after treatment.
In addition, among those patients who had out-PTVifi
in-PTVeni cervical nodes metastasis, only 1 patient (14%)
in the ENI group received salvage radiotherapy after the
failure. However, 5 patients (63%) in the IFI group had
salvage radiotherapy.
Toxicity
There were 6 patients (6%) in the IFI group and 4 pa-
tients (6%) in the ENI group experiencing grade ≥ 3
treatment-related esophageal injuries (p > 0.05). Grade 3
acute esophagitis were observed in 8 patients, 5 in the
IFI group and 3 in the ENI group. Grade 4 acute esopha-
gitis were observed in 2 patients, one in the IFI group
and the other in the ENI group. Grade 3 late esophageal
injuries were exhibited in 3 patients, 1 in the IFI group
and 2 in the ENI group. Grade 4 late esophageal injuries
were exhibited in one patient in the IFI group.
Grade ≥ 3 treatment-related lung injury occurred in 2
patients (2%) in the IFI group and 3 patients (4%) in the
ENI group, respectively (p > 0.05). Grade 3 acute radi-
ation induced pneumonitis was observed in 4 patients, 2in the IFI group and 2 in the ENI group. Grade 3 radi-
ation induced lung fibrosis was exhibited in one patient
in the ENI group. Grade 4 radiation induced lung injury
was not found.
Discussion
The necessity of ENI for esophageal cancer has always
been controversial [5-10], especially for ENI of the low
neck. In the 1980s, regardless of tumor locations, the ra-
diation field covered from supraclavicular region down
to the joint region between esophagus and stomach [2].
However, involved field irradiation (IFI) has been used
more frequently in the past decade [11]. We reported
the outcome of 53 esophageal SCC who underwent de-
finitive concurrent chemoradiation with IFI. We found
that the median OS time was 30 months and 85% of
patients failed locoregionally inside the irradiation fields,
suggesting the un-necessity of ENI [5]. Yamashita also
found that ENI was not helpful in the improvement of
OS, and it brought higher rate of treatment-related
deaths [6]. Zhang XL et al. performed a retrospective
study on the failure patterns of 80 patients who under-
went IFI, and found that the solitary regional nodal fail-
ure of out-of-field was acceptable for them [9]. However,
ENI reduced the rates of distant lymph nodes metastasis
in Hsu FM et al.’s study [10]. Onozawa M. et al. also
showed ENI was effective for preventing regional nodal
failure [12]. In Amini’s study, the celiac axis acts was
considered as a “gateway” to the abdomen, and there-
fore, the coverage of celiac axis nodes was recom-
mended, particularly for distal esophageal tumors [13].
For the cervical and upper thoracic esophageal cancers,
it was speculated logically that ENI of low neck would
be worthwhile due to the network of lymphatic commu-
nication. Chen JQ et al. reported that of the 1850 pa-
tients with thoracic esophageal SCC who underwent
surgery, 1081 (58.4%) developed lymph nodes metastasis.
The lymphatic metastatic rates were 35.6% for the cer-
vical nodes. For the upper esophageal SCC, the most
common node metastasis was in the cervical (49.5%)
[14]. However,few reports have been published in the
literature with regards to the comparison of detailed
failure patterns between ENI and IFI.
In our retrospective study, 169 cervical and upper
thoracic esophageal SCC were irradiated with or without
ENI. OS, in-field recurrence incidence and distal organ
metastasis rate were quite similar between the two
groups. ENI did not reduce the cervical node progres-
sion rates. Ten percent of the patients in the ENI group
had out-PTVifi in-PTVeni nodes metastasis, and 8%
patients in the IFI group had such failures.
Moreover, we also found that for the patients in the
IFI group, all the out-PTVifi in-PTVeni occurred within
2 years after treatment.In contrast, for patients in the
Table 3 Out-PTVifi in-PTVeni cervical nodes metastasis
Patients no. Radiation Disease progress Time to progress
(months)
Next site Salvage treatment
1 ENI Cervical nodes 13 Brain metastasis BSC
2 ENI Cervical nodes and lung metastasis 15 Esophageal progress BSC
3 ENI Cervical nodes and in-field recurrence 12 In-field nodes recurrence BSC
4 ENI Cervical nodes 35 Multiple metastasis Chemotherapy
5 ENI Cervical nodes and esophagus 16 Esophageal progress and
other nodes metastasis
Target therapy and palliative
radiotherapy
6 ENI Cervical nodes and other nodes
metastasis
44 Multiple metastasis Chemotherapy
7 ENI Cervical nodes and esophagus 24 Esophageal progress BSC
8 IFI Cervical nodes and esophagus 4 Mediastinal nodes BSC
9 IFI Cervical nodes 5 Pharynx cancer Radiotherapy and chemotherapy
10 IFI Cervical and other nodes 20 Multiple nodes metastasis Radiotherapy
11 IFI Cervical nodes and esophagus 10 Mediastinal nodes BSC
12 IFI Cervical nodes and esophagus 1 Mediastinal and celiac nodes
and bone metastasis
BSC
13 IFI Cervical nodes 11 Esophageal tumor progress Radiotherapy
14 IFI Cervical nodes 13 Multiple nodes metastasis Chemoradiotherapy
15 IFI Cervical nodes and esophagus 7 Esophageal progress Surgery and radiotherapy
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year after treatment. Therefore, our results supported
that elective irradiation of low neck might not be able to
decrease the rate of cervical nodes progression in the
elective field. It could only delay these failures. In additionFigure 2 Probability of Out-PTVifi in-PTVeni cervical nodes metastasisto that, earlier onset of cervical nodes progression in the
elective field had no influence to both further failures
(Table 3) and OS. On the contrary, it might bring higher
rates of treatment related esophageal toxicity. Though no
significant increase of esophageal toxicity was found fromin the ENI group and the IFI group.
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a statistically significant increase of radiation-induced
side-effects and radiation-related death in esophageal SCC
patients who underwent ENI.
From another perspective, due to previous cervical
prophylactic radiation, only one patient in the ENI group
underwent palliative radiotherapy after nodes metastasis
in the out-PTVifi in-PTVeni field. However, in the IFI
group, 63% of patients received salvage cervical radiation
after these failures. More treatment opportunities after
disease progression may contribute to the better prog-
nostic result of patients in the IFI group.
In conclusion, ENI did not significantly improve OS
and long-term control of cervical nodes in cervical and
upper thoracic esophageal SCC patients. However, it is a
retrospective study and included a small number of
patients. Also it is a limitation that not all the patients
had PET/CT, for PET/CT is not covered by insurance in
China and many patients could not afford the expense.
Therefore, this finding should be validated in further
prospective studies.
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